Protagonist Therapeutics, Inc
PTGX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001377121
In the last 90 days, Protagonist Therapeutics, Inc insiders filed 0 open-market purchases and 2 sales; 346 institutions reported holding it in 13F filings for Q2 2026, worth $9.30B in total; Duquesne Family Office is the only superinvestor holding it.
Key figures
- Market capClose on Nov 11, 2026
- $8.80B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $26.6M in total
- 2
- 13F holdersQ2 2026, +27 vs. previous quarter
- 346
- 13F valueReported value at the end of Q2 2026
- $9.30B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $46.0M
- −89.4% year over year
- Net income, FY2025
- -$130.1M
- −147.3% year over year
- Free cash flow, FY2025
- $56.1M
- −69.3% year over year
- Revenue, Q3 FY2026
- $274.4M
- +5,723.6% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $130.1M (282.8% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 10.2M
- Shares sold short
- Change
- −54.9K
- −0.5% vs. previous
- Days to cover
- 16.89
- At average daily volume
Superinvestors holding PTGX, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Protagonist Therapeutics, Inc on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.6%
Protagonist Therapeutics, Inc's share of the portfolio
- Shares
- 208,900
- Value
- $25.6M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Protagonist Therapeutics, Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 2026 (view filing)4:10 PM ET | Sep 30 | 2 days | Ali AsifChief Financial Officer | SSale | −58.6K | $141.78 | −$8.31M | −49.8%59.0K after | 2 lots10b5-1 |
| Sep 10, 2026 (view filing)9:17 PM ET | Sep 8-10 | 2 days | Patel Dinesh V PH DPresident and CEO | SSale | −125.0K | $145.92 | −$18.2M | −19.3%523.0K after | 3 lots10b5-1 |
| Aug 12, 2026 (view filing)6:43 PM ET | Aug 10-11 | 2 days | Patel Dinesh V PH DPresident and CEO | SSale | −100.0K | $148.91 | −$14.9M | −16.0%523.5K after | 2 lots10b5-1 |
| Jun 25, 2026 (view filing) | Jun 23 | 2 days | Waddill William D.Director | SSale | −9.00K | $117.94 | −$1.06M | −53.5%7.83K after | 10b5-1 |
| Jun 11, 2026 (view filing) | Jun 10 | 1 day | Waddill William D.Director | SSale | −9.00K | $107.68 | −$969.1K | −53.5%7.83K after | 10b5-1 |
| Jun 1, 2026 (view filing) | May 29 | 3 days | Waddill William D.Director | SSale | −9.00K | $99.64 | −$896.8K | −53.5%7.83K after | 10b5-1 |
| May 14, 2026 (view filing) | May 12 | 2 days | Patel Dinesh V PH DPresident and CEO | SSale | −75.0K | $100.12 | −$7.51M | −12.5%523.5K after | Amended10b5-1 |
| May 11, 2026 (view filing) | May 7-8 | 4 days | Giraudo BryanDirector | SSale | −41.1K | $100.12 | −$4.12M | −76.4%12.7K after | 2 lots |
| May 11, 2026 (view filing) | May 7-8 | 4 days | Giraudo BryanDirector | SSale | −18.0K | $100.05 | −$1.80M | −100.0%0 after | 2 lots |
| Apr 21, 2026 (view filing) | Apr 20 | 1 day | Ali AsifChief Financial Officer | SSale | −1.75K | $105.47 | −$184.6K | −2.9%59.0K after |
Top 10 13F holders, Q2 2026
See all 346 holdersThe largest institutional positions in Protagonist Therapeutics, Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,307,837 | $1.26B | 0.02% | +528,468+5.4% | Added |
| Farallon Capital Management, L.L.C. | 6,348,906 | $778.2M | 4.56% | 00.0% | Unchanged |
| RTW Investments, LP | 5,061,175 | $620.4M | 5.30% | +2,1220.0% | Added |
| Vanguard Portfolio Management LLC | 3,629,298 | $444.9M | 0.02% | +148,087+4.3% | Added |
| Wellington Management Group LLP | 3,416,781 | $418.8M | 0.07% | −182,863−5.1% | Reduced |
| UBS Group AG | 3,399,221 | $416.7M | 0.07% | −1,778,575−34.4% | Reduced |
| State Street Corp | 3,321,554 | $407.2M | 0.01% | +204,805+6.6% | Added |
| Vanguard Capital Management LLC | 2,853,394 | $349.8M | 0.01% | +47,498+1.7% | Added |
| Johnson & Johnson | 2,449,183 | $300.2M | 37.59% | 00.0% | Unchanged |
| Invesco Ltd. | 2,340,667 | $286.9M | 0.02% | +175,997+8.1% | Added |
Holders of 5% or more of PTGX
See all 8 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Protagonist Therapeutics, Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 15.20%9.83M shares | +1.40 ppfrom 13.80% | Feb 5, 20254 filings | Oct 27, 2026 | SEC |
| Farallon Capital Management, L.L.C. | 13G/A | 9.99%6.43M shares | – | Feb 16, 20213 filings | Aug 13, 2026 | SEC |
| Farallon Capital Partners, L.P. | 13G/A | 9.99%6.25M shares | 0.00 ppfrom 9.99% | Feb 9, 20234 filings | Feb 6, 2026 | SEC |
| RTW Investments, LP | 13G/A | 8.10%5.06M shares | – | Feb 12, 20215 filings | Feb 17, 2026 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.53%3.53M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |